Dizal Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Dizal Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).
Dizal Pharmaceuticals: 15 sponsored US clinical trials, 2 recruiting.
Dizal Pharmaceuticals sponsors 15 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 10 completed. 1 of these trials are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Non-Small Cell Lung Cancer, with 3 trials.
Top-decile sponsor footprint
Dizal Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
10 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
15 total, page 1 of 1
A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)
NCT06905197
DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT05824585
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
NCT05668988
Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
NCT03974022
DZD9008 PK Study in Hepatic Impairment Subjects
NCT06084104
Drug-drug Interactions Between AZD4205 and Itraconazole/Carbamazepine
NCT05486949
Drug-drug Interactions Between DZD9008 and Itraconazole/Carbamazepine
NCT05418582
Pharmacokinetic and Mass Balance Study of Oral-Administrated [14C]-DZD9008 in Healthy Male Subjects
NCT05159895
A Study of DZD2269 in Healthy Adult Participants
NCT04932005
Assessing the Safety, Tolerability and Pharmacokinetics(PK) of DZD9008 and the Effect of Low-fat Meal on PK of DZD9008 in Healthy Adult Participants
NCT04909242
Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC
NCT04634344
DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer
NCT04509596
Pharmacokinetic and Mass Balance Study of Orally Administered [14C]-AZD4205 in Healthy Adult Male Volunteers
NCT04225208
Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)
NCT04105010
A Study of AZD4205 in Healthy Adult Subjects
NCT03728023
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 14 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the Dizal Pharmaceuticals pipeline
2 recruiting of 15 indexed (13% open); 10 completed (67%).
Phase mix: 1 late (III/IV) vs 14 early (I/II) (early-phase heavy).
Top condition: Non-Small Cell Lung Cancer (3 trials), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Dizal Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 15 registered trials and 13% open enrollment, not the therapeutic-area sidebar.
Dizal Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 15 trials (± recruiting share)
- Allakos · 15 trials · 0% recruiting
- Arbor Research Collaborative for Health · 15 trials · 33% recruiting
- Arena Pharmaceuticals · 15 trials · 0% recruiting
- Arrowhead Pharmaceuticals · 15 trials · 20% recruiting
Sponsors near 13% open enrollment (± trial volume)
- Chiesi Farmaceutici S.p.A. · 13% recruiting · 30 trials
- Edgewise Therapeutics · 13% recruiting · 15 trials
- EpicentRx · 13% recruiting · 15 trials
- European Organisation for Research and Treatment of Cancer - EORTC · 13% recruiting · 15 trials
Related
What to do with this Dizal Pharmaceuticals page
15 registered trials is a research-attention snapshot, not an endorsement of Dizal Pharmaceuticals or any single study.
- 2 of Dizal Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Non-Small Cell Lung Cancer is the condition Dizal Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Non-Small Cell Lung Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Dizal Pharmaceuticals pipeline card: 15 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.